Clinical trials: Intensive Care Unit Acquired Weakness
ICU Acquired Weakness
Safety and Efficacy of the MyokinE100 (CL-EMS Alpha) Device in Inducing Visible Muscle Contraction in Healthy Volunteers
Every patient admitted to the Intensive Care Unit (ICU) is at risk of developing "Intensive Care Unit Acquired Weakness" (ICUAW).
- Trial name
- NCT06023511
- Testing
- Electrical muscle stimulation
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Health Discovery Labs
Sepsis
Dysfunctions of Human Muscle Stem Cells in Sepsis
Severe critical illness is often complicated by Intensive Care Unit - Acquired Weakness (ICU-AW), which is associated with increased in and post-ICU mortality, with delayed weaning from mechanical ventilation and with long-term…
- Trial name
- DISCUSS (NCT02789995)
- Testing
- Human biological samples
- Where
- 7 sites in France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Sepsis, Critical Illness
MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients
The goal of this clinical trial is to learn if a new medical device that sends electrical signals to the thigh muscles is safe and easy to use for people in the ICU (Intensive Care Unit) who are at risk of losing muscle strength.
- Conditions
- Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness
- Trial name
- ICUAW (NCT07362862)
- Testing
- Electrical Muscle Stimulation System
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Health Discovery Labs
ICU Acquired Weakness
Evaluation of FDY-5301 in Major Trauma Patients in ICU
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)
- Trial name
- NCT04430283
- Testing
- FDY-5301
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Faraday Pharmaceuticals, Inc.